Pfiz­er seeds di­a­betes up­start An­Tol­Rx with cash and an op­tion deal

Pfiz­er is back­ing a new­ly mint­ed biotech that is right at the very ear­li­est stage of tak­ing an aca­d­e­m­ic pro­gram out of a Har­vard lab and see­ing if it can trans­late it in­to a suc­cess­ful de­vel­op­ment ef­fort for Type 1 di­a­betes.

The new com­pa­ny is An­Tol­Rx, based in Cam­bridge’s Kendall Square, which now has four full timers and a few key helpers as it builds a new pro­gram around a nanopar­ti­cle ap­proach to si­mul­ta­ne­ous­ly present an anti­gen and tol­er­ance mol­e­cule to tamp down the au­toim­mune re­sponse that caus­es di­a­betes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.